Aug 01, 2019 / 07:00AM GMT
Shigeo Taniuchi - Santen Pharmaceutical Co., Ltd. - President, COO, Head of North America Business & Representative Director
[Interpreted] Hello. My name is Taniuchi, President and Chief Operating Officer. I would like to explain the highlights of Q1 fiscal year 2019 results.
On Page 2 and 3, we have the mission statement and also the policies of the midterm plan. 2019 is the second year of MTP2020. As you know, in our company, we have Vision 2020, which is a 10-year long-term plan which began in 2011, and MTP2020 is the last 3 years of Vision 2020. And 2019 is the second year of MTP2020. We have been involved in various reforms and also growth based upon new products. And in the first quarter of this year, we have been able to focus on these aspects as well to incur growth.
On Page 4 is the highlights. We have made a strong start toward achievement of fiscal year 2019 full year forecast, and we are very happy about that. Revenue, JPY 59.1 billion, which was an increase of JPY 2.7 billion and 4.7% growth. And core operating profit was JPY 12.8 billion, which was a 9.6% growth. So we
Q1 2020 Santen Pharmaceutical Co Ltd Earnings Call Transcript
Aug 01, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers